Amgen's stock is facing significant pressure following a disappointing market response to recent clinical trial results.
Amgen Inc. (NASDAQ:AMGN) saw its stock decline by 6.86% today, closing at CA$407.25. This drop comes after disappointing news regarding its drug pipeline, especially in light of recent trial results from competitors that have overshadowed Amgen's advancements.
Advertisement
Amgen Inc
AMGN.US
AMGN.US
Amgen Inc
WealthAwesomeMarket cap
$203.47B
P/E
23.3x
Div. yield
2.61%
Div. / share
$9.80
52W high
$447.03
52W low
$262.49
1W change
-3.81%
Beta
0.43
Analyst Price Targets
Based on 32 analysts covering AMGN · as of Sep 17, 2026
Wall Street analysts forecast AMGN stock price to rise 1297.3% over the next 12 months.
Consensus
Buy3.63 / 5.00
Avg. Target
C$388.03
+1297.3% Upside
Current Price
C$27.77
Last close
Analyst Breakdown (32 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AMGN's historical volatility
30-Day Vol
38.0%
Annualized
90-Day Vol
33.1%
Annualized
Trend (90d)
+40.3%
Annualized drift
90d Mean
C$438.65
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$398.47 | C$349.55 – C$454.23 |
| 60 trading days | C$418.07 | C$347.38 – C$503.16 |
| 90 trading days | C$438.65 | C$349.61 – C$550.36 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be cautious as Amgen's recent setbacks in clinical trials could signal tougher competition and potential revenue impacts moving forward.
6.86% Decline
Amgen's stock fell significantly today, reflecting investor concerns over competitive pressures and pipeline uncertainties.
Bull case
Amgen is still a leader in biopharmaceuticals with a strong portfolio. Its ongoing research has the potential to yield positive results that could help restore investor confidence.
Bear case
Recent trial failures and competitive pressures reveal vulnerabilities in Amgen's pipeline, raising concerns about future growth and profitability.
Advertisement
Market Reaction to Competitive Pressures
Amgen's stock faced a notable decline today, driven mainly by worries about its competitive position in the oncology market. Recent trial results from Novartis have raised alarms, suggesting that Amgen may struggle to maintain its market share against innovative therapies from rivals. This reaction highlights how sensitive biotech stocks are to clinical trial outcomes, especially when competitors show significant advancements.
Implications for Amgen's Future
The decline in Amgen's stock raises questions about the sustainability of its growth trajectory. With a market cap of approximately CA$236.38 billion and a P/E ratio of 27.174, investors are now closely examining the company's ability to deliver on its pipeline promises. As the landscape of cancer treatment evolves, Amgen must navigate these challenges carefully to reassure investors and maintain its position as a leader in the biopharmaceutical sector.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
